Important Notice for Intellia Therapeutics, Inc. (NTLA) Shareholders
New York, NY, February 27, 2025 – The Gross Law Firm, a leading securities fraud class action law firm, notifies investors that a class action has been commenced in the United States District Court for the Southern District of New York on behalf of shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA) who purchased shares during the period from November 18, 2020, to December 16, 2022, inclusive (the “Class Period”).
Background
Intellia Therapeutics, Inc. is a leading genome editing company focused on developing curative therapies using the CRISPR/Cas9 system. The company’s mission is to bring transformative gene-edited medicines to patients with genetic diseases.
The Allegations
The complaint alleges that throughout the Class Period, Intellia made materially false and misleading statements regarding the company’s business, operations, and financial condition. Specifically, the complaint alleges that Intellia failed to disclose that:
- The company’s lead product candidate, INT-200, was not making the desired progress in clinical trials;
- The company’s manufacturing processes were not producing sufficient quantities of INT-200 for clinical trials;
- The company’s collaboration with Regeneron Pharmaceuticals, Inc. was not progressing as planned;
- The company’s financial statements were materially false and misleading.
Effect on Shareholders
As a result of this alleged false and misleading information, Intellia’s stock traded at artificially inflated prices during the Class Period, causing investors harm.
Effect on the World
The implications of this securities fraud class action extend beyond Intellia’s shareholders. The biotech industry as a whole could face increased scrutiny and skepticism, potentially dampening investor confidence and slowing the pace of innovation. Furthermore, the outcome of this case could set a precedent for future securities fraud cases in the industry.
What You Can Do
If you purchased shares of Intellia Therapeutics, Inc. during the Class Period, you may be entitled to compensation. The Gross Law Firm urges you to contact the firm as soon as possible to discuss your legal rights and potential appointment as a lead plaintiff in this action. You can contact the firm by calling 888-227-1188 or by sending an email to [email protected].
The Gross Law Firm represents investors worldwide and accepts cases on a contingency fee basis. The firm advances the costs of the litigation and receives payment only if there is a recovery.
Conclusion
The Gross Law Firm’s securities fraud class action against Intellia Therapeutics, Inc. highlights the importance of transparency and accuracy in corporate communications. Shareholders who purchased NTLA during the Class Period are encouraged to contact the firm to discuss their potential recovery options. The outcome of this case could have far-reaching implications for the biotech industry and investor confidence.
For more information about The Gross Law Firm or the Intellia Therapeutics, Inc. securities fraud class action, please visit www.grosslawfirm.com/securities/intellia-therapeutics-inc or call 888-227-1188.
